High-precision detection of therapeutic antibody concentration and functional properties alongside their dynamic changes enables therapeutic antibody monitoring of both therapeutic antibodies and anti-drug antibodies (ADA). The integration of near-infrared microarray protein chip technology enables our comprehensive support in biologics efficacy evaluation, personalized patient management, and drug development. Monitoring therapeutic antibody serum levels (e.g., adalimumab's minimum effective concentration<10 ng/mL) and ADA neutralizing activity (IC50 determination) enables prediction of treatment response, dosing optimization, and early detection of immunogenicity risks.

• Drug Efficacy Evaluation: Serum concentration monitoring to predict therapeutic response intensity.
• ADA Screening: Early detection of patient-developed anti-drug antibodies, assessing immunogenicity in biosimilars.
• Dosing Optimization: Dynamic concentration tracking to refine regimens (e.g., PD-1 inhibitor minimum effective thresholds).
• Safety Risk Mitigation: Neutralizing activity analysis of ADAs to forecast drug efficacy decline.